Avidity Biosciences, Inc. is a pioneering biopharmaceutical company dedicated to revolutionizing treatment modalities using its unique platform based on antibody oligonucleotide conjugates (AOCs™). AOCs are essentially therapeutic proteins conjugated with therapeutic RNA molecules capable of targeting specific cells. Founded in 2013, Avidity Biosciences has its headquarters stationed in La Jolla, California.
Avidity Biosciences is leveraging the power of antibody-drug conjugate technology, synergizing it with RNA therapeutics – a disruptive new dimension in the world of medicine. This union creates a multi-modal opportunity to create ‘potent’ therapeutics. The company's advanced technology allows them to develop transformative medicines for diseases that were once considered untreatable. Currently, Avidity Biosciences has become known for its work on myotonic dystrophy type 1 (DM1) and other muscle-related disorders with considerable unmet medical needs.
AOCs, Avidity's proprietary method, transports oligonucleotides in the body with significantly higher efficacy. This technology makes it possible to address diseases at the genetic level, a capability that further differentiates Avidity in the field of biopharmaceutical companies.
Avidity has gathered an expert team who carry the combined knowledge of antibody engineering, conjugation chemistry, and oligonucleotide therapies. The team of experienced professionals includes individuals who have made groundbreaking advancements in the field of RNA therapies.
In June 2020, Avidity Biosciences completed its initial public offering (IPO), which highlights the interest and investment potential of its unique blend of technologies. The company is focused on scientific discovery and drug development, with an open alliance model that effectively encourages partnerships with academia and other biotechnology and pharmaceutical companies.
Despite being a relatively young company, Avidity Biosciences, Inc. has made significant strides in creating innovative therapeutics, showing its potential to contribute to the future of medicine. As the company continues to develop and refine its technologies, it aims to produce transformative therapies for patients with limited treatment options. With the AOCs technology providing a league of advanced capabilities, Avidity Biosciences is poised to revolutionize the developmental therapeutics industry.